Personal record-keeping and educational reference. 18+. The app does not recommend substances, doses or treatment, or determine whether a substance is safe, approved or appropriate for you. Consult a qualified healthcare professional about decisions involving your health.
‹ Library

Adipotide

Fat LossResearch Use Only

Also known as: FTPP, prohibitin-targeting peptide, CKGGRAKDC-GG-D(KLAKLAK)2

An experimental compound that targets the blood supply of fat tissue. Development stopped over kidney safety — treat with caution.

Dosing quick reference

research reference
Starting dose
250 mcg once daily
Frequency
Once daily
Typical range
250–1,000 mcg per day
Cycle
4–8 weeks (short, cautious cycles)
Titration (step-up)
Increase 250 mcg every 2 weeks as tolerated
Clinical development was discontinued (reversible kidney toxicity in trials).
Half-life
Short (reported in preclinical data)
Route
Subcutaneous (research)
Common use
Preclinical adipose-tissue research
Common vial sizes
10 mg
Storage
Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.
Stacking notes
Early-stage research compound; combination use is not characterized in the literature.

Reported side effects

Renal effects reported in animal studiesDehydration signs in preclinical models
Regulatory note: Not approved for human use in Canada or the US; experimental compound studied primarily in animal models. Research-grade material is not for human use.
Calculate a dose →Adipotide on The Peptide Guide →Deeper research reference: literature dose ranges, storage and handling, and where to source in Canada.

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.